We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Ardelyx, Inc.
Health Care · Biotechnology
Structural: dual commercial franchises on a single molecule (tenapanor) targeting large IBS-C and CKD dialysis markets; Medicare 2025 reimbursement for XPHOZAH removes the key payer overhang that suppressed the stock in 2023-2024.
XPHOZAH dialysis penetration still early (<10% of ~550k US dialysis patients); IBS-C market underpenetrated vs. Linzess/Trulance; operating leverage as SG&A scales sub-linearly; partnership optionality with Kyowa Kirin for Japan XPHOZAH rights.
dialysis formulary adoption slower than modeled (DaVita/Fresenius P&T cycles); generic tenapanor IP risk post-2033; cash burn if ramp lags; competitive pressure from Auryxia and phosphate binders in CKD.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.